PCR-based Analysis News
-
MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a renowned reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers to efficiently ...
By CD Genomics
-
Release of a new reference material for the detection of SARS-CoV-2 by RT-PCR.
The JRC released a new reference material for the detection of SARS-CoV-2 by real time RT-PCR. The material consists of a synthetic ssRNA (EURM-014) covering a fraction of the viral genome. It will be particularly useful for clinical or environmental diagnostic laboratories seeking quality and trust in their SARS-CoV-2 measurements. In 2020, the JRC issued a synthetic ssRNA molecule (EURM-019) ...
-
How the COVID-19 PCR Test Works
The COVID-19, pandemic amongst other changes in our lifestyle, has introduced us to new medical terms that we are not quite familiar with, such as the term PCR (polymerase chain reaction). As you may already know, PCR is a method to detect SARS-COV-2 virus, more specifically its nucleic acid. It is the “golden standard” of SARS-2 detection, as declared by the World Health Association ...
-
FireGene's Monkeypox Virus Nucleic Acid Detection Kit (Real-time PCR Method) Receives CE-IVDD Certification
FireGene announces that its Monkeypox Virus Nucleic Acid Detection Kit (Real-time Fluorescent PCR Method) has recently obtained CE-IVDD approval. This RT-PCT kit can be used to detect suspected cases of MPV infection. Rash fluid, nasopharyngeal swabs, pharyngeal swabs, and serum samples are applicable for the test. The test result is available in 40 minutes after sample collection. This kit is ...
By FireGene
-
Amerigo Scientific Launches Anex® Brush for Optimal Sampling
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the release of a new Anex® Brush that allowed optimal sampling the entire anal canal including the anal transformation zone, without the need for a proctoscope or anoscope. Amerigo Scientific provides high-quality and cost-effective medical ...
-
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
-
miDiagnostics launches its CE-IVD certified ultra-fast COVID-19 PCR Test
The Test is now available for use across Europe and other countries that accept CE-IVD marking, providing a powerful pandemic and endemic management tool in industries where fast and reliable decentralized testing is crucial. With the launch of its first product, miDiagnostics enters the commercial phase, marking an important milestone in the company’s development. Ultra-fast and reliable ...
-
Infant Bacterial Therapeutics publishes Annual Report for 2021
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...
-
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Corporation ...
-
The transformation of precision medicine in infectious disease
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
-
20 Healthtech Innovations to watch in 2022
HiberGene Diagnostics are delighted to be recognised as one of Irelands ‘20 Healthtech innovations to watch in 2022’. Thanks to the support from the Health Innovation Hub Ireland, HiberGene were able to work with Bon Secours Health System Ireland, Cork in carrying out a very successful clinical evaluation of its PCR Adapt Covid-19 test, with excellent results. Clinical Need The ...
-
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
By Osel Inc.
-
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientific ...
-
Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit*, and TaqPath COVID-19 CE-IVD RT-PCR Kit*, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results. The Omicron variant, which was designated a "variant ...
-
New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth
As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward. The Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System is a compact instrument that easily transitions from ...
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...
-
City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
By Osel Inc.
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
Eligo Presents Preclinical Data Demonstrating for the First Time that Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome), at the 14th Annual CRISPR 2021 meeting held June 1-10, 2021. The data presented further supports ...
-
Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab improved ...
By Osel Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you